ArticleBMC microbiology2026
A target-guided drug repurposing strategy for antibacterial discovery.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe scarcity of effective antibiotics against drug-resistant pathogens has intensified the need for alternative antibacterial development strategies. Drug repurposing (DR) offers a practical solution; herein, we present detailed experimental workflows and in vitro results to validate the feasibility of a DR-based strategy for new antibacterial development.
methodsUsing Vina-GPU, we performed molecular docking between 125 highly conserved bacterial essential proteins and 2,027 approved non-antibacterials drugs to predict drug-target interactions. As preliminary screening, 14 candidate drugs were tested for inhibitory activity against six bacterial strains (Escherichia coli MC4100, Pseudomonas aeruginosa PAO1, Acinetobacter baumannii ATCC 19606, Salmonella enterica Typhi CMCC 50071, Salmonella enterica Typhimurium ATCC 14028, and Klebsiella oxytoca ATCC 13182) at 100 μg/ml. Subsequently, lower-concentration assays (combined with Polymyxin B nonapeptide, PMBN) were conducted for preliminarily active drugs. The FLUOStar Omega was used to measure bacterial suspension optical density (OD₆₀₀) and calculate drug inhibition rates. Surface plasmon resonance (SPR), MD simulation, and folate rescue experiments were used to further validate the mechanism of the drug.
resultsAmong the 2,027 non-antibacterials drugs, several exhibited antibacterial activities. Additionally, 173 existing antibacterials were clustered into two groups based on their binding affinity similarity to the 125 essential proteins, with the two groups showing distinct antibacterial activities. Notably, multiple repurposed drugs inhibited the growth of multiple bacterial species.
conclusionOur study revealed that the combination of 8 μg/ml lifitegrast and PMBN can effectively inhibit six gram-negative bacteria. Folate rescue experiments showed that the preliminary antibacterial mechanism of lifitegrast is to inhibit the function of FolA. In addition, future research should explore the structure-activity relationship of lifitegrast and its impact on antibacterial activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.